质子泵抑制剂在乳腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2017.02.017

Abstract

Abstract: In recent years,some studies have been shown that proton pump inhibitors(PPIs)not only play a role in digestive diseases,but it also has an important role in the treatment of breast cancer.PPIs,including omeprazole,pantoprazole,lansoprazole,esomeprazole,etc,improve the effect of breast cancer chemotherapy and induce breast cancer cell apoptosis by inhibiting intracellular proton excretion and increasing intracellular pH.This preview summarizes the study progress of PPIs in breast cancer and the potential application of PPIs in the treatment of breast cancer.

Key words: Proton pump inhibitors, Breast cancer, Omeprazole, Pantoprazole

CLC Number:

R737.9

FU Yingqiang,LI Zhigao. Research progress of proton pump inhibitors on breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 179-182.

References

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2016[J].Ca A Cancer Journal for Clinicians,2016,66(1):7.
2 Moulder S,Hortobagyi GN.Advances in the treatment of breast cancer[J].Womens Health,2005,1(3):359-363.
3 Zhang S,Wang Y,Li SJ.Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion[J].Biochem Biophys Res Commun,2014,448(4):424-429.
4 Wang BY,Zhang J,Wang JL,et al.Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer[J].J Exp Clin Cancer Res,2015,34(1):85.
5 Man Y,Lee C,Wang M,et al.Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors[J].Cancer Sci,2015,106(10):1438-1447.
6 Patel KJ,Lee C,Tan Q,et al.Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin:a potential strategy to improve the therapy of solid tumors[J].Clin Cancer Res,2013,19(24):6766-6776.
7 Goh W,Sleptsova-Freidrich I,Petrovic N.Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers.An introductory study[J].J Pharm Pharm Sci,2014,17(3):439-446.
8 Jin UH,Lee SO,Pfent C,et al.The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis[J].BMC Cancer,2014,14(14):498.
9 刘波,姚鸿萍.临床常用质子泵抑制剂的研究进展[J].西北药学杂志,2014(3):328-330.
10 Shin JM,Kim N.Pharmacokinetics and pharmacodynamics of the proton pump inhibitors[J].J Neurogastroenterol Motil,2013,19(1):25-35.
11 毛煜,佘佳红,袁伯俊.苯并咪唑类质子泵抑制剂的药理和临床研究进展[J].中国新药杂志,2006,15(1):17-21.
12 Rogakou EP,Pilch DR,Orr AH,et al.DNA double-stranded breaks induce histone H2AX hosphorylation on serine 139[J].J Biol Chem,1998,273:5858-5868.
13 Chen YN,Mickley LA,Schwartz AM,et al.Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein[J].J Biol Chem,1990,265:10073-10080.
14 Lee JS,Scala S,Matsumoto Y,et al.Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression[J].J Cell Biochem,1997,65:513-526.
15 Litman T,Brangi M,Hudson E,et al.The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter,MXR(ABCG2)[J].J Cell Sci,2000,113:2011-2021.
16 Poland A,Glover E,Kende AS.Stereospecific,high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol.Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase[J].J Biol Chem,1976,251(16):4936-4946.
17 Dinatale BC,Schroeder JC,Francey LJ,et al.Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling[J].J Biol Chem,2010,285(32):24388-24397.
18 Murray IA,Krishnegowda G,DiNatale BC,et al.Development of a selective modulator of aryl hydrocarbon(Ah)receptor activity that exhibits anti-inflammatory properties[J].Chem Res Toxicol,2010,23(5):955-966.
19 Benson JM,Shepherd DM.Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn′s disease[J].Toxicol Sci,2011,120(1):68-78.
20 Murray IA,Morales JL,Flaveny CA,et al.Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity[J].Mol Pharmacol,2010,77(2):247-254.
21 Boitano AE,Cooke MP.Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells[J].Science,2010,329(5997):1345-1348.
22 Quintana FJ,Basso AS,Iglesias AH,et al.Control of T(reg)and T(H)17 cell differentiation by the aryl hydrocarbon receptor[J].Nature,2008,453(7191):65-71.
23 Veldhoen M,Hirota K,Westendorf AM,et al.The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins[J].Nature,2008,453(7191):106-109.
24 Kerkvliet NI,Steppan LB,Vorachek W,et al.Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes[J].Immunotherapy,2009,1(4):539-547.
25 Hsu EL,Yoon D,Choi HH,et al.A proposed mechanism for the protective effect of dioxin against breast cancer[J].Toxicol Sci,2007,98(2):436-444.
26 Hall JM,Barhoover MA,Kazmin D,et al.Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation[J].Mol Endocrinol,2010,24(2):359-369.
27 Wang T,Gavin HM,Arlt VM,et al.Aryl hydrocarbon receptor activation during pregnancy,and in adult nulliparous mice,delays the subsequent development of DMBA-induced mammary tumors[J].Int J Cancer,2011,128(7):1509-1523.
28 Di Paolo A,Bocci G.Drug distribution in tumors,mechanisms,role in drug resistance,and methods for modification[J].Curr Oncol Rep,2007,9(2):109-114.
29 Minchinton AI,Tannock IF.Drug penetration in solid tumours[J].Nat Rev,2006,6(8):583-592.
30 Simon S,Roy D,Schindler M.Intracellular pH and the control of multidrug resistance[J].Proc Natl Acad Sci USA,1994,91(3):1128-1132.
31 Tannock IF,Rotin D.Acid pH in tumors and its potential for therapeutic exploitation[J].Cancer Res,1989,49(16):4373-4384.
32 Rotin D,Robinson B,Tannock IF.Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells:potential implications for cell death in tumors[J].Cancer,1986,46(6):2821-2826.
33 Helmlinger G,Sckell A,Dellian M,et al.Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism[J].Clin Cancer Res,2002,8(4):1284-1291.
34 Gillies RJ,Liu Z,Bhujwalla Z.31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate[J].Am J Physiol,1994,267(1):195-203.
35 Mccoy CL,Parkins CS,Chaplin DJ,et al.The effect of blood flow modification on intra-and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours[J].Br J Cancer,1995,72(4):905-911.
36 Raghunand N,He X,Van SR,et al.Enhancement of chemotherapy by manipulation of tumour pH[J].Br J Cancer,1999,80(7):1005-1011.
37 Liu H,Liu JY,Wu X,et al.Biochemistry,molecular biology,and pharmacology of fatty acid synthase,an emerging therapeutic target and diagnosis/prognosis marker[J].Int J Biochem Mol Biol,2010,1:69-89.
38 De Schrijver E,Brusselmans K,Heyns W,et al.RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells[J].Cancer Res,2003,63:3799-3804.
39 Zhou W,Simpson PJ,McFadden JM,et al.Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells[J].Cancer Res,2003,63(21):7330-7337.

[1]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[2]	LI Shuo,ZHANG Nannan,LI Liangliang,LONG Zhiping,YIN Huihui,ZHAO Yashuang,WANG Fan. Relationship between PDE4C gene methylation in peripheral blood leukocytes,interaction of environmental factors and pathogenesis of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 233-238.
[3]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[4]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[5]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[6]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.
[7]	HE Xu, YE shangmian, DONG dandan, LI Ke. The expression of HLA-G in breast cancer and its significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 410-414.
[8]	LIN Rongjie, YIN Hang, ZHOU Yunfeng. Effect of ON123300 on ER+ human breast cancer MCF-7 cells and its mechanism [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 193-197.
[9]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[10]	ZHENG Wei, XU Shouping, PANG Da. Expression,prognosis and function of long chain non-coding RNA-Linc00152 in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 7-13.
[11]	YIN Yulian, ZHANG Weihong, ZHOU Yue, YE Meina, CHEN Hongfeng. Correlation between single nucleotide polymorphisms of ERα gene and bone loss associated with aromatase inhibitors in postmenopausal women with breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 14-18.
[12]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.
[13]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.
[14]	LI Hongyang, SUN Liang, JIANG Xing, YUAN Guangjun, LIU Yan. Dauricine enhances the sensitivity of 5-fluorouracil in human breast cancer MCF-7 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 385-389.
[15]	LUO Jianing, HAO Chuncheng, ZHANG Jianxin, LU Jiangyue, GE Xiaofeng. Effect of postoperative adjuvant radiotherapy on prognosis of triple-negative breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 411-416.

Research progress of proton pump inhibitors on breast cancer

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments